Perampanel: as adjunctive therapy in patients with partial-onset seizures (Q38062397)

28 August 2017

1 reference

title

Perampanel: as adjunctive therapy in patients with partial-onset seizures (English)

1 reference

28 August 2017

1 reference

1

Greg L Plosker

1 reference

28 August 2017

1 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

26

1 reference

28 August 2017

12

1 reference

28 August 2017

1085-1096

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-012-0021-2

28 August 2017

0 references

cites work

Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Pharmacotherapy of epilepsy: newly approved and developmental agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

21 January 2018

Drug-resistant epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

The natural history of epilepsy: an epidemiological view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Comorbidity, health screening, and quality of life among persons with a history of epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

The neurobiology of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Molecular targets for antiepileptic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Revisiting AMPA receptors as an antiepileptic drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Tolerability and safety of perampanel: two randomized dose-escalation studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0021-2

Perampanel Study 207: long-term open-label evaluation in patients with epilepsy

21 January 2018

1 reference

12 December 2020

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

1 reference

12 December 2020

The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?

1 reference

12 December 2020

Glutamate as a neurotransmitter in the brain: review of physiology and pathology

1 reference

12 December 2020

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305

1 reference

12 December 2020

The epidemiology of the epilepsies

1 reference

12 December 2020

10.1007/S40263-012-0021-2

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23179642